Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
| dc.contributor.author | Bakirtas, M | |
| dc.contributor.author | Dal, MS | |
| dc.contributor.author | Yigenoglu, TN | |
| dc.contributor.author | Giden, AO | |
| dc.contributor.author | Serin, I | |
| dc.contributor.author | Basci, S | |
| dc.contributor.author | Kalpakci, Y | |
| dc.contributor.author | Korkmaz, S | |
| dc.contributor.author | Ekinci, O | |
| dc.contributor.author | Albayrak, M | |
| dc.contributor.author | Basturk, A | |
| dc.contributor.author | Ozatli, D | |
| dc.contributor.author | Dogu, MH | |
| dc.contributor.author | Hacibekiroglu, T | |
| dc.contributor.author | Çakar, MK | |
| dc.contributor.author | Ulas, T | |
| dc.contributor.author | Miskioglu, M | |
| dc.contributor.author | Gulturk, E | |
| dc.contributor.author | Eser, B | |
| dc.contributor.author | Altuntas, F | |
| dc.date.accessioned | 2025-04-10T10:37:04Z | |
| dc.date.available | 2025-04-10T10:37:04Z | |
| dc.description.abstract | A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least >= two lines of therapy. Patients' treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 +/- 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients. | |
| dc.identifier.e-issn | 1973-9478 | |
| dc.identifier.issn | 1120-009X | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/42806 | |
| dc.language.iso | English | |
| dc.title | Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey | |
| dc.type | Article |